MedWatch

Merck Ventures invests in Novo Seeds company

A British biotech company, which develops next generation immunotherapies and counts Novo Seeds among its owners, has been given a sizeable sum from Germany’s Merck Ventures.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Genmab søger om ny godkendelse hos EMA

I Europa vil Genmab nu til at have hovedproduktet, Darzalex, godkendt til førstelinjebehandling for knoglemarvskræft. Det udløser en ny milepælsbetaling fra partneren Janssen. (Opdateret 13.35)

Latest Top picks in English

Related articles